• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Raised levels of antistreptokinase antibody and neutralization titres from 4 days to 54 months after administration of streptokinase or anistreplase.

作者信息

Lee H S, Cross S, Davidson R, Reid T, Jennings K

机构信息

Department of Cardiology, Aberdeen Royal Infirmary, Scotland.

出版信息

Eur Heart J. 1993 Jan;14(1):84-9. doi: 10.1093/eurheartj/14.1.84.

DOI:10.1093/eurheartj/14.1.84
PMID:8432298
Abstract

Streptokinase and anistreplase are antigenic and their administration often leads to antibody formation. These can cause allergic reactions and/or neutralization of streptokinase with resulting suboptimal treatment. Currently, streptokinase re-administration is considered appropriate for up to 5 days and from 1 year after a previous dose. Antistreptokinase antibody and neutralization titres (NT) were measured in three groups of patients to determine if this practice is appropriate: 1. (early)--36 patients whose titres were measured for at least 5 days after thrombolysis; 2. (late)--57 patients who received thrombolysis 12-54 months previously; 3. (controls)--182 consecutive suspected myocardial infarction patients (without previous exposure to thrombolysis). Results were as follows (mean +/- SEM): 1. (early)--the antibody and/or NT were raised by day 4 in 19.4% of the patients. One patient could have neutralized 1.97 million units (MU) of streptokinase by day 4. (Day 4--antibody 1:39 +/- 11, NT 0.19 +/- 0.05 MU; day 5--1:136 +/- 41 and NT 0.7 +/- 0.43 MU respectively.) 2. (late)--23 patients (40%) had either antibody titres > or = 1:160 and/or NT > 1.5 MU. (12-23 months--antibody 1:243 +/- 43, NT 0.63 +/- 0.15 MU; 24-35 months--1:98 +/- 31 and 0.69 +/- 0.22 MU; 36-54 months--1:87 +/- 14 and 0.54 +/- 0.12 MU.) All titres were significantly higher than the controls (antibody 1:25 +/- 3, NT 0.14 +/- 0.01 MU, P < 0.01). After streptokinase or antistreplase, antibodies are raised from 4 days to at least 54 months. It would seem prudent to avoid their re-administration during this time interval.

摘要

相似文献

1
Raised levels of antistreptokinase antibody and neutralization titres from 4 days to 54 months after administration of streptokinase or anistreplase.
Eur Heart J. 1993 Jan;14(1):84-9. doi: 10.1093/eurheartj/14.1.84.
2
Hypersensitivity reactions to streptokinase in patients with high pre-treatment antistreptokinase antibody and neutralisation titres.
Eur Heart J. 1993 Dec;14(12):1640-3. doi: 10.1093/eurheartj/14.12.1640.
3
Monitoring of streptokinase resistance titre in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase IgG.对急性心肌梗死患者在给予链激酶或阿尼普酶后长达30个月的链激酶抗性滴度进行监测,以及进行相关研究以测定特异性抗链激酶IgG。
Br Heart J. 1992 Aug;68(2):167-70. doi: 10.1136/hrt.68.8.167.
4
Lack of influence of pretreatment antistreptokinase antibody on efficacy in a multicenter patency comparison of intravenous streptokinase and anistreplase in acute myocardial infarction.
Am Heart J. 1992 Aug;124(2):305-14. doi: 10.1016/0002-8703(92)90591-i.
5
Antistreptokinase titres after intravenous streptokinase.
Lancet. 1990 Jan 27;335(8683):184-5. doi: 10.1016/0140-6736(90)90276-b.
6
Effect of intrapleural streptokinase administration on antistreptokinase antibody level in patients with loculated pleural effusions.
Chest. 2003 Feb;123(2):432-5. doi: 10.1378/chest.123.2.432.
7
Neutralizing antibodies to streptokinase four years after intravenous thrombolytic therapy.
Am J Cardiol. 1993 Mar 15;71(8):640-5. doi: 10.1016/0002-9149(93)91003-z.
8
Streptokinase resistance: when might streptokinase administration be ineffective?链激酶抵抗:何时使用链激酶可能无效?
Br Heart J. 1992 Nov;68(5):449-53. doi: 10.1136/hrt.68.11.449.
9
Streptokinase neutralisation titres up to 866 days after intravenous streptokinase for acute myocardial infarction.急性心肌梗死静脉注射链激酶后长达866天的链激酶中和效价。
Br Heart J. 1993 Aug;70(2):119-21. doi: 10.1136/hrt.70.2.119.
10
Drug eruptions and isotypic antibody responses to streptokinase after infusions of anisoylated plasminogen-streptokinase complex (APSAC, anistreplase).输注茴香酰化纤溶酶原-链激酶复合物(APSAC,茴酰化纤溶酶原链激酶激活剂复合物)后出现的药物疹及对链激酶的同型抗体反应。
J Allergy Clin Immunol. 1995 May;95(5 Pt 1):1020-8. doi: 10.1016/s0091-6749(95)70103-6.

引用本文的文献

1
A rapid agglutination assay to detect anti-streptokinase antibodies.一种检测抗链激酶抗体的快速凝集试验。
Ir J Med Sci. 2004 Oct-Dec;173(4):204-10. doi: 10.1007/BF02914552.
2
Profiling the immune responses of human patients treated with recombinant streptokinase after myocardial infarct.分析心肌梗死后接受重组链激酶治疗的人类患者的免疫反应。
Mol Divers. 2004;8(3):251-6. doi: 10.1023/b:modi.0000036235.45565.50.
3
BTS guidelines for the management of pleural infection.英国胸科学会胸膜感染管理指南。
Thorax. 2003 May;58 Suppl 2(Suppl 2):ii18-28. doi: 10.1136/thorax.58.suppl_2.ii18.
4
An Angiographic Study of Intracoronary Streptokinase versus Intravenous Tissue Plasminogen Activator After Failed Coronary Thrombolysis with Intravenous Streptokinase.
J Thromb Thrombolysis. 1996;3(3):239-243. doi: 10.1007/BF00181666.
5
Criteria for drug usage review of thrombolytics in acute myocardial infarction.
Pharmacoeconomics. 1995 Jan;7(1):25-38. doi: 10.2165/00019053-199507010-00004.
6
Antibodies to streptokinase.抗链激酶抗体。
BMJ. 1996 Feb 17;312(7028):393-4. doi: 10.1136/bmj.312.7028.393.
7
Are streptokinase antibodies clinically important?链激酶抗体在临床上重要吗?
Br Heart J. 1993 Dec;70(6):590. doi: 10.1136/hrt.70.6.590-a.
8
Pre-dosing antibody levels and efficacy of thrombolytic drugs containing streptokinase.含链激酶溶栓药物的给药前抗体水平及疗效
Br Heart J. 1994 Sep;72(3):222-5. doi: 10.1136/hrt.72.3.222.
9
Rural Alberta thrombolysis study. Survey of practice patterns for managing acute myocardial infarction.艾伯塔省农村溶栓研究。急性心肌梗死管理实践模式调查。
Can Fam Physician. 1995 Jul;41:1180-7.
10
Does the potential for development of streptokinase antibodies change the risk-benefit ratio in older patients?
Drugs Aging. 1995 Aug;7(2):110-6. doi: 10.2165/00002512-199507020-00005.